These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 17361231)

  • 1. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.
    Rawstron AC; Villamor N; Ritgen M; Böttcher S; Ghia P; Zehnder JL; Lozanski G; Colomer D; Moreno C; Geuna M; Evans PA; Natkunam Y; Coutre SE; Avery ED; Rassenti LZ; Kipps TJ; Caligaris-Cappio F; Kneba M; Byrd JC; Hallek MJ; Montserrat E; Hillmen P
    Leukemia; 2007 May; 21(5):956-64. PubMed ID: 17361231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.
    Rawstron AC; Böttcher S; Letestu R; Villamor N; Fazi C; Kartsios H; de Tute RM; Shingles J; Ritgen M; Moreno C; Lin K; Pettitt AR; Kneba M; Montserrat E; Cymbalista F; Hallek M; Hillmen P; Ghia P;
    Leukemia; 2013 Jan; 27(1):142-9. PubMed ID: 23041722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.
    Böttcher S; Ritgen M; Pott C; Brüggemann M; Raff T; Stilgenbauer S; Döhner H; Dreger P; Kneba M
    Leukemia; 2004 Oct; 18(10):1637-45. PubMed ID: 15343348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis.
    Böttcher S; Stilgenbauer S; Busch R; Brüggemann M; Raff T; Pott C; Fischer K; Fingerle-Rowson G; Döhner H; Hallek M; Kneba M; Ritgen M
    Leukemia; 2009 Nov; 23(11):2007-17. PubMed ID: 19641522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR.
    Raponi S; Della Starza I; De Propris MS; Del Giudice I; Mauro FR; Marinelli M; Di Maio V; Piciocchi A; Foà R; Guarini A
    Br J Haematol; 2014 Aug; 166(3):360-8. PubMed ID: 24735016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice.
    Stehlíková O; Chovancová J; Tichý B; Krejčí M; Brychtová Y; Panovská A; Francová Skuhrová H; Burčková K; Borský M; Loja T; Mayer J; Pospíšilová S; Doubek M
    Int J Lab Hematol; 2014 Apr; 36(2):165-71. PubMed ID: 24028768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry.
    Dowling AK; Liptrot SD; O'Brien D; Vandenberghe E
    Lab Med; 2016 May; 47(2):103-11. PubMed ID: 27069028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.
    Montillo M; Schinkoethe T; Elter T
    Cancer Invest; 2005; 23(6):488-96. PubMed ID: 16203656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens.
    Rawstron AC; de Tute R; Jack AS; Hillmen P
    Leukemia; 2006 Dec; 20(12):2102-10. PubMed ID: 17051247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stem cell transplantation in poor-risk chronic lymphocytic leukemia: assessment of post-transplant minimal residual disease using four- and six-color flow cytometry and allele-specific RQ-PCR.
    Itälä M; Huhtinen AR; Juvonen V; Kairisto V; Pelliniemi TT; Penttilä TL; Rauhala A; Tienhaara A; Remes K
    Eur J Haematol; 2008 Aug; 81(2):100-6. PubMed ID: 18410542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia.
    Pfitzner T; Reiser M; Barth S; Borchmann P; Schulz H; Schinköthe T; Oberhäuser F; Wessels J; Tur M; Diehl V; Engert A
    Ann Hematol; 2002 May; 81(5):258-66. PubMed ID: 12029535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease assessment in chronic lymphocytic leukaemia.
    Sayala HA; Rawstron AC; Hillmen P
    Best Pract Res Clin Haematol; 2007 Sep; 20(3):499-512. PubMed ID: 17707836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normal levels of peripheral CD19(+) CD5(+) CLL-like cells: toward a defined threshold for CLL follow-up -- a GEIL-GOELAMS study.
    Durrieu F; Geneviève F; Arnoulet C; Brumpt C; Capiod JC; Degenne M; Feuillard J; Garand R; Kara-Terki A; Kulhein E; Maynadié M; Ochoa-Noguera ME; Plesa A; Roussel M; Eghbali H; Truchan-Graczyk M; de Carvalho Bittencourt M; Feugier P; Béné MC
    Cytometry B Clin Cytom; 2011 Nov; 80(6):346-53. PubMed ID: 21976156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR.
    Kerst G; Kreyenberg H; Roth C; Well C; Dietz K; Coustan-Smith E; Campana D; Koscielniak E; Niemeyer C; Schlegel PG; Müller I; Niethammer D; Bader P
    Br J Haematol; 2005 Mar; 128(6):774-82. PubMed ID: 15755280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel flow-cytometric analysis based on BCD5+ subpopulations for the evaluation of minimal residual disease in chronic lymphocytic leukaemia.
    Maloum K; Sutton L; Baudet S; Laurent C; Bonnemye P; Magnac C; Merle-Béral H
    Br J Haematol; 2002 Dec; 119(4):970-5. PubMed ID: 12472575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
    Böttcher S; Ritgen M; Buske S; Gesk S; Klapper W; Hoster E; Hiddemann W; Unterhalt M; Dreyling M; Siebert R; Kneba M; Pott C;
    Haematologica; 2008 Apr; 93(4):551-9. PubMed ID: 18379010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry.
    Sarasquete ME; García-Sanz R; González D; Martínez J; Mateo G; Martínez P; Ribera JM; Hernández JM; Lahuerta JJ; Orfão A; González M; San Miguel JF
    Haematologica; 2005 Oct; 90(10):1365-72. PubMed ID: 16219573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
    Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
    Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.
    Rawstron AC; Fazi C; Agathangelidis A; Villamor N; Letestu R; Nomdedeu J; Palacio C; Stehlikova O; Kreuzer KA; Liptrot S; O'Brien D; de Tute RM; Marinov I; Hauwel M; Spacek M; Dobber J; Kater AP; Gambell P; Soosapilla A; Lozanski G; Brachtl G; Lin K; Boysen J; Hanson C; Jorgensen JL; Stetler-Stevenson M; Yuan C; Broome HE; Rassenti L; Craig F; Delgado J; Moreno C; Bosch F; Egle A; Doubek M; Pospisilova S; Mulligan S; Westerman D; Sanders CM; Emerson R; Robins HS; Kirsch I; Shanafelt T; Pettitt A; Kipps TJ; Wierda WG; Cymbalista F; Hallek M; Hillmen P; Montserrat E; Ghia P
    Leukemia; 2016 Apr; 30(4):929-36. PubMed ID: 26639181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Touch-down reverse transcriptase-PCR detection of IgV(H) rearrangement and Sybr-Green-based real-time RT-PCR quantitation of minimal residual disease in patients with chronic lymphocytic leukemia.
    Peková S; Marková J; Pajer P; Dvorák M; Cetkovský P; Schwarz J
    Mol Diagn; 2005; 9(1):23-34. PubMed ID: 16035732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.